Myasthenia Gravis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Myasthenia Gravis Therapeutics Market Analysis
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face, and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased. these factors have helped this market grow.
However, the cost of treatment still remains high for the disease. This has been restraining the market growth.
Myasthenia Gravis Therapeutics Market Trends
This section covers the major market trends shaping the Myasthenia Gravis Therapeutics Market according to our research experts:
Medications are Expected to Cover a Large Share of the Market
There are two primary therapies for the treatment of Myasthenia Gravis. Symptomatic treatment (acetylcholinesterase inhibition) is used to increase the amount of acetylcholine (ACh) available at the neuromuscular junction and Chronic immunosuppressive therapies (glucocorticoids and nonsteroidal immunosuppressive agents) are used to target the underlying immune dysregulation are the two primary therapies.
Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. Moreover, research and development are being done to further improve the efficacy of these medications
North America is Expected to Dominate the Myasthenia Gravis Market
According to Myasthenia Gravis Foundation Of America 2019 data, the prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, which approximately translates to 36,000 to 60,000 cases in the United States. However, the report states that myasthenia gravis may be underdiagnosed in many cases and the prevalence might be higher. Report also suggests that women are more often affected than men. The most common age at onset is the 20s and 30s in women and the 60s and 70s in men.
However, the developed North American countries like the US and Canada have well structured and development healthcare systems. These countries also promote research and development for rare diseases and hence have very high expenditure on healthcare. As a result of these policies, many companies globally are encouraged to operate in this region.
Moreover, most of the population in developed countries like the US and Canada are covered under medical and health insurance and hence, are able to afford the expensive medication and therapies for myasthenia gravis. Hence, the North American region is expected to cover a large share of the myasthenia gravis market.
Myasthenia Gravis Therapeutics Industry Overview
Majority of the myasthenia gravis therapeutics are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness and this has also helped the market grow.
Myasthenia Gravis Therapeutics Market Leaders
-
Alexion Pharmaceuticals Inc
-
Mitsubishi Tanabe Pharma
-
Astellas Pharma
-
Bausch Health
-
UCB S.A.
*Disclaimer: Major Players sorted in no particular order
Myasthenia Gravis Therapeutics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Incidence of Myasthenia Gravis
-
4.2.2 Increasing Research and Development for Myasthenia Gravis
-
-
4.3 Market Restraints
-
4.3.1 High Cost of Treatment
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment
-
5.1.1 Medication
-
5.1.2 Surgery
-
5.1.3 Others
-
-
5.2 By End-User
-
5.2.1 Hospitals
-
5.2.2 Clinics
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Alexion Pharmaceutical Inc.
-
6.1.2 Argenx
-
6.1.3 Astellas Pharma
-
6.1.4 CuraVac
-
6.1.5 Grifols SA
-
6.1.6 Immunovant
-
6.1.7 Mitsubishi Tanabe Pharma
-
6.1.8 Novartis
-
6.1.9 UCB Pharma
-
6.1.10 Bausch Health
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Myasthenia Gravis Therapeutics Industry Segmentation
Myasthenia gravis is a neuromuscular autoimmune disorder that causes weakness in the skeletal muscles, which are the muscles your body uses for movement. It occurs when communication between nerve cells and muscles becomes impaired. This impairment prevents crucial muscle contractions from occurring, resulting in muscle weakness. Although there is no cure for the disorder, medications may be used to prevent the exacerbation of symptoms.
| By Treatment | |
| Medication | |
| Surgery | |
| Others |
| By End-User | |
| Hospitals | |
| Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Myasthenia Gravis Therapeutics Market Research FAQs
What is the current Myasthenia Gravis Therapeutics Market size?
The Myasthenia Gravis Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Myasthenia Gravis Therapeutics Market?
Alexion Pharmaceuticals Inc, Mitsubishi Tanabe Pharma, Astellas Pharma, Bausch Health and UCB S.A. are the major companies operating in the Myasthenia Gravis Therapeutics Market.
Which is the fastest growing region in Myasthenia Gravis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Myasthenia Gravis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Myasthenia Gravis Therapeutics Market.
What years does this Myasthenia Gravis Therapeutics Market cover?
The report covers the Myasthenia Gravis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Myasthenia Gravis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Myasthenia Gravis Therapeutics Industry Report
Statistics for the 2024 Myasthenia Gravis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Myasthenia Gravis Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
